Ph 3 INTerpath-002 Study of V940 (mRNA-4157) – KEYTRUDA combination for Adjuvant Treatment of Patients with Certain Types of Resected NSCLC December 19, 2023
First Patient Dosed in Ph 2b Trial of Samuraciclib + Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer December 19, 2023
Enrollment of Ph 2/3 Trial of Fruquintinib + Sintilimab for Advanced RCC in China completed December 19, 2023
Confirmatory Ph 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer initiated December 19, 2023
First Patient Enrolled in Ph 2 Study of BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu December 11, 2023
STELLAR-305 Ph 2/3 Pivotal Trial of Zanzalintinib + Keytruda in Patients with 1L Recurrent or Metastatic Head and Neck Cancer announced December 11, 2023
First Patient Dosed in Ph 1a Trial of QN-302 in Advanced or Metastatic Solid Tumors December 11, 2023
Patient Enrollment in Global Ph 3 Trial of Buparlisib (AN2025) + Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC completed December 11, 2023
First Patient Dosed in Ph 1 Trial of ORB-011 in Patients with Advanced Solid Tumors November 20, 2023
Successful Completion of Safety Cohort and Positive DSMB Results from TCB008’s Trial in AML Patients Announced November 15, 2023
Completion of the Safety Lead-In and Opening of Ph 2 of the AIPAC-003 Ph 2/3 Trial in Metastatic Breast Cancer Announced November 7, 2023
First Patient Dosed in the Registrational Ph 3 Study of Olverembatinib in 1L Ph+ ALL Patients October 25, 2023
First Patients Dosed in First-in-Human Ph 1 Study of FX-909 in Advanced Solid Tumors, Including Urothelial Cancer October 25, 2023
Enrollment ex-China in Ph 3 REGAL Trial for Galinpepimut-S in AML Expected to be Completed in Nov 2023 October 18, 2023
Clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab and cetuximab to be discontinued October 18, 2023
